Presentation is loading. Please wait.

Presentation is loading. Please wait.

Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD 

Published byGlenna Hardja Modified over 5 years ago

Similar presentations

Presentation on theme: "Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD "— Presentation transcript:

1 Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer 
Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD  Journal of Thoracic Oncology  Volume 10, Issue 12, Pages (December 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Radiotherapy induces multiple immunomodulatory changes that can potentially influence the effectiveness of immunotherapy. Shown above from left to right and in Table 1: radiation may lead to direct tumor cell killing; upregulation of immunogenic cell surface markers, such as mhc-1; secretion of danger signals and cytokines, such as TNF-alpha; induction of immunogenic cell death via calreticulin and HMGB-1, among others; improved homing of immune cells, such as cytotoxic T lymphocytes to tumor; improved antigen presentation by mechanism including priming of dendritic cells; a shift in TAM from the M2 to M1 phenotype; and upregulation of cell surface PD-L1, among others. MHC-1, major histocompatibility complex 1; HMGB-1, high mobility group protein B1; TAM, tumor-associated macrophage; PD-L1, programmed cell death ligand-1. Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD "

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Figure 5 Dendritic cells in liver inflammation

Figure 5 Dendritic cells in liver inflammation
Oncology Meets Immunology: The Cancer-Immunity Cycle

Oncology Meets Immunology: The Cancer-Immunity Cycle
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig 
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor  Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Targets for immunotherapy of liver cancer

Targets for immunotherapy of liver cancer
Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD 

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD 
Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G
Robert J Korst, MD, Ronald G Crystal, MD 

Robert J Korst, MD, Ronald G Crystal, MD 

Similar presentations

Ads by Google